Publications
195
Citations
9,269
Est. group size
~2
Recurring co-author estimate
Active years
61
Publishing since 1966
Typically publishes in teams of ~14 · 2% small-team papers (≤3 authors) · across 19 venues
- NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
Journal of Clinical Oncology · 2026
- Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer
ESMO Gastrointestinal Oncology · 2026
- Hepatic Arterial Infusion Therapy: Considerations for Concurrent Systemic Therapy
2025
- Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Nature Medicine · 2024
- Baseline MRI predictors of successful organ preservation in the Organ Preservation in Rectal Adenocarcinoma (OPRA) trial
British journal of surgery · 2024
- Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
Journal of Clinical Oncology · 2023
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet · 2023
- Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2023
- A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology · 2023
- A phase1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer.
Journal of Clinical Oncology · 2023
- ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).
Journal of Clinical Oncology · 2023
- 93P Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Annals of Oncology · 2023
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
Journal of Clinical Oncology · 2022
- Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With<i>BRAF</i>Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
JCO Precision Oncology · 2022
- 45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Annals of Oncology · 2022
- Journal of Clinical Oncology×24
- Annals of Oncology×13
- Figshare×5
- Journal of Thoracic Oncology×3
- Journal of the American Medical Informatics Association×2
- Mingjia Li
Medicine · The Ohio State University
- J. Kevin Hicks
Medicine · University of Michigan
- Yusuf Açıkgöz
Medicine · The Ohio State University
- Ha Tran
Medicine · The Ohio State University
- Osama Alkhalili
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile